Scolaris Content Display Scolaris Content Display

Mast cell stabilisers for seasonal and perennial allergic conjunctivitis

Esta versión no es la más reciente

Referencias

Additional references

Abelson 2001

Abelson MB. Allergic Disease of the Eye. Philadelphia: WB Saunders, 2001.

Apgar 2000

Apgar B. New drugs for allergic conjunctivitis. Medical Letter on Drugs and Therapeutics 2000;42(1077):39‐40.

Aït‐Khaled 2009

Aït‐Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009;64(1):123‐48.

Bacon 2000

Bacon AS, Ahluwalia P, Irani AM, Schwartz LB, Holgate ST, Church MK, et al. Tear and conjunctival changes during the allergen‐induced early‐ and late‐phase responses. Journal of Allergy and Clinical Immunology 2000;106(5):948‐54.

BenEzra 2006

BenEzra D. Blepharitis and Conjunctivitis. Guidelines for Diagnosis and Treatment. 1st Edition. Barcelona: Editorial Glosa, 2006.

Bruijnzeel 1989

Bruijnzeel PLB,  Warringa RAJ,  Kok PTM. Inhibition of platelet‐activating factor and zymosan‐activated serum‐induced chemotaxis of human neutrophils by nedocromil sodium, BN 52021 and sodium cromoglycate. British Journal of Pharmacology 1989;97(4):1251‐7.

Buckley 1998

Buckley RJ. Allergic eye disease‐‐a clinical challenge. Clinical and Experimental Allergy 1998;28(Suppl 6):39‐43.

Calderon 2011

Calderon MA,  Penagos M,  Sheikh A,  Canonica GW,  Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD007685.pub2]

Cerqueti 1994

Cerqueti PM, Ricca V, Tosca MA, Buscaglia S, Ciprandi G. Lodoxamide treatment of allergic conjunctivitis. International Archives of Allergy and Immunology 1994;105(2):185‐9.

Chauvin 2002

Baush, Lomb Chauvin (France). OSD (Ocular Surface Disease Questionnaire ‐ Pathologies de la Surface Oculaire). www.mapi‐trust.org/services/questionnairelicensing/cataloguequestionnaires/119‐osd (accessed 11 March 2012).

Cochrane Eyes and Vision Group module 2011

Azuara‐Blanco A, Bunce C, Burr J, Dickersin K, Diener‐West M, Elliott S, et al. Cochrane Eyes and Vision Group. About The Cochrane Collaboration 2011, Issue 1. Art. No.: [EYES].

Dart 1986

Dart JK. Eye disease at a community health centre. British Medical Journal 1986;293(6560):1477‐80.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Edwards 2005

Edwards AM. The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology. Journal of Allergy and Clinical Immunology 2005;115(4):885‐8.

Freissler 1997

Freissler KA, Lang GE, Lang GK. Allergic diseases of the lids, conjunctiva, and cornea. Current Opinion in Ophthalmology 1997;8(4):25‐30.

Friday 1983

Friday GA, Biglan AW, Hiles DA, Murphey SM, Miller DL, Rothbach C, et al. Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution. American Journal of Ophthalmology 1983;95(2):169‐74.

Gamble 2005

Gamble C, Hollis S. Uncertainty method improved on best‐worst case analysis in a binary meta‐analysis. Journal of Clinical Epidemiology 2005;58(6):579‐88.

Glanville 2006

Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6.

Green 2005

Green S, Higgins J, editors. Glossary. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http://www.cochrane.org/resources/handbook/ (accessed 4 May 2010).

Higgins 2011a

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Higgins 2011b

Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Janssen 1998

Janssen LJ, Wattie J, Betti PA. Effects of cromolyn and nedocromil on ion currents in canine tracheal smooth muscle. European Respiratory Journal 1998;12(1):50‐6.

Kay 1987

Kay AB,  Walsh GM,  Moqbel R,  MacDonald AJ,  Nagakura T,  Carroll MP,  et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro . Journal of Allergy and Clinical Immunology 1987;80(1):1‐8.

Kunkel 1985

Kunkel G, Baumer FE, Okuda M, van Cauwenberge P. Mode of action and indication for disodium cromoglycate (DSCG). Allergologia et Immunopathologia 1985;13(4):285‐9.

Larsson 2001

Larsson K,  Larsson BM,  Sandström T,  Sundblad BM,  Palmberg L. Sodium cromoglycate attenuates pulmonary inflammation without influencing bronchial responsiveness in healthy subjects exposed to organic dust. Clinical and Experimental Allergy 2001;31(9):1356‐68.

Leonardi 1999

Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmologica Scandinavica. Supplement 1999;228:21‐3.

Loke 2011

Loke YK, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

López Pérez 2009

López Pérez G, Morfín Maciel BM, Huerta López J, Mejía Covarrubias F, López López J, Aguilar G, et al. Prevalence of allergic disease in Mexico city [Prevalencia de las enfermedades alérgicas en la Ciudad de México]. Revista Alergia México 2009;56(3):72‐9.

Manners 1997

Manners T. Managing eye conditions in general practice. BMJ 1997;315(7111):816‐7.

McCormick 1995

McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice Fourth National Study 1991‐1992 A Study Carried Out by the Royal College of General Practitioners, the Office of Population Censuses & Surveys, & the Department of Health. London: HMSO, 1995.

McDonnell 1988

McDonnell PJ. How do general practitioners manage eye disease in the community?. British Journal of Ophthalmology 1988;72(10):733‐6.

McGill 1998

McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A. Allergic eye disease mechanisms. British Journal of Ophthalmology 1998;82(10):1203‐14.

Melamed 1994

Melamed J, Schwartz RH, Hirsch SR, Cohen SH. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Annals of Allergy 1994;73(1):57‐66.

Mishra 2011

Mishra GP, Tamboli V, Jwala J, Mitra AK. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Patents on Inflammation and Allergy Drug Discovery 2011;5(1):26‐36.

Montan 1994

Montan P, Zetterstrom O, Eliasson E, Stromquist LH. Topical sodium cromoglycate (Opticrom) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes. Allergy 1994;49(8):637‐40.

Moqbel 1988

Moqbel R,  Cromwell O,  Walsh GM,  Wardlaw AJ,  Kurlak L,  Kay AB. Effects of nedocromil sodium (TILADE) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988;43(4):268‐76.

Mustafa 2012

Mustafa MS, Castillo M, Mustafa MZ, Scott N, Azuara‐Blanco A. Topical antihistamines for treating seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD009566]

Möller 1994

Möller C, Berg IM, Berg T, Kjellman M, Strömberg L. Nedocromil sodium 2% eye drops for twice‐daily treatment of seasonal allergic conjunctivitis: a Swedish multicentre placebo‐controlled study in children allergic to birch pollen. Clinical and Experimental Allergy 1994;24(9):884‐7.

Ono 2005

Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. Journal of Allergy and Clinical Immunology 2005;115(1):118‐22.

Owen 2004

Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta‐analysis of efficacy and effectiveness. British Journal of General Practice 2004;54(503):451‐6.

Pitt 2004

Pitt AD,  Smith AF,  Lindsell L,  Voon LW,  Rose PW,  Bron AJ. Economic and quality‐of‐life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiology 2004;11(1):17‐33.

Rabin 2011

Rabin R, Oemar M, Oppe M. EQ‐5D‐3L User Guide: Basic information on how to use the EQ‐5D‐3L instrument. www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ‐5D‐3L.pdf (accessed 27 July 2012).

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, TheCochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Rosario 2011

Rosario N,  Bielory L. Epidemiology of allergic conjunctivitis. Current Opinion in Allergy and Clinical Immunology 2011;11(5):471‐6.

Ruggieri 1987

Ruggieri ML, Scorcia G. Double‐blind group comparative trial of sodium cromoglycate eye ointment and placebo in the treatment of allergic eye diseases. Annals of Allergy 1987;58(2):109‐12.

Schiffman 2000

Schiffman RM,  Christianson MD,  Jacobsen G,  Hirsch JD,  Reis BL. Reliability and validity of the Ocular Surface Disease Index. Archives of Ophthalmology 2000;118(5):615‐21.

Sign 2010

Scottish Intercollegiate Guidelines Network (SIGN). Search filters for randomised controlled trials. www.sign.ac.uk/methodology/filters.html#random (accessed 13 November 2012).

Simon‐Licht 1982

Simon‐Licht IF, Dieges PH. A double‐blind clinical trial with cromoglycate eye drops in patients with atopic conjunctivitis. Annals of Allergy 1982;49(4):220‐4.

Singh 2010

Singh K,  Axelrod S,  Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988‐1994. Journal of Allergy and Clinical Immunology 2010;126(4):778‐83.e6.

Smith 2005

Smith AF,  Pitt AD,  Rodruiguez AE,  Alio JL,  Marti N,  Teus M,  et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiology 2005;12(4):233‐42.

Stahl 1999

Stahl JL, Cook EB, Graziano FM, Barney NP. Human conjunctival mast cells: expression of Fc epsilonRI, c‐kit, ICAM‐1, and IgE. Archives of Ophthalmology 1999;117(4):493‐7.

Sterne 2011

Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Stockwell 1994

Stockwell A, Easty DL. Group comparative trial of 2% nedocromil sodium with placebo in the treatment of seasonal allergic conjunctivitis. European Journal of Ophthalmology 1994;4(1):19‐23.

Takamura 2011

Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, et al. Japanese guideline for allergic conjunctival diseases. Allergology International 2011;60(2):191‐203.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment (Winchester, England) 199;3(5):iii‐92.

Yazid 2009

Yazid S,  Solito E,  Christian H,  McArthur S,  Goulding N,  Flower R. Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx‐A1. Biochemical Pharmacology 2009;77(12):1814‐26.
Table 1. Glossary

Adverse effect

Unfavourable outcome that occurs during or after the use of a drug or other intervention for which the causal relation between the intervention and the event is at least a reasonable possibility (Loke 2011).

Available case analysis

Analysis that includes data on only those whose results are known, using as a denominator the total number of people who had data recorded for the particular outcome in question (Higgins 2011a).

Funnel plot

Simple scatter plot of the intervention effect estimates from individual studies against some measure of each study’s size or precision (Sterne 2011).

Intention‐to‐treat analysis

Analysis that fulfils the next principles:
1. keeps participants in the intervention groups to which they were randomised, regardless of the intervention they actually received;
2. there is a measurement of outcome data on all participants; and
3. includes all randomised participants in the analysis (Higgins 2011a).

Unit of analysis errors

An error made in statistical analysis when the analysis does not take account of the unit of allocation. In some studies, the unit of allocation is not a person, but is instead a group of people, or parts of a person, such as eyes or teeth. Sometimes the data from these studies are analysed as if people had been allocated individually. Using individuals as the unit of analysis when groups of people are allocated can result in overly narrow confidence intervals. In meta‐analysis, it can result in studies receiving more weight than is appropriate (Green 2005).

Small‐study effects

A tendency for estimates of the intervention effect to be more beneficial in smaller studies (Sterne 2011).

Figuras y tablas -
Table 1. Glossary